AN OPEN LABEL, MULTI-CENTER ROLL-OVER STUDY TO ASSESS LONG-TERM EFFECT IN PEDIATRIC PATIENTS TREATED WITH TAFINLAR (DABRAFENIB) AND/OR MEKINIST (TRAMETINIB)

Registry ID

CDRB436G2401

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2024-06-17

Last update

2019-07-03

Conditions

• BRAF MUTATION-POSITIVE TUMORS

Related clinical trials

• A PHASE 1 AND PHARMACOKINETIC STUDY OF DABRAFENIB (GSK2118436B) IN PATIENTS WITH BRAFV600X MUTATIONS AND RENAL OR HEPATIC DYSFUNCTION.

View on source registry